Recent study also suggested most recurrent luminal B subtype enriched fusions were including ESR1 in metastatic setting and 5% of HR positive treatment refractory metastatic BC (MBC) harbored ESR1 fusion30. The gene discussed is ESR1; the disease is breast cancer.